Pelthos Therapeutics Inc.

Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building a portfolio of differentiated cutaneous infectious disease products addressing unmet patient needs. Its lead product, Zelsuvmi (berdazimer topical gel, 10.3%), is the first and only FDA-approved prescription therapy for at-home treatment of molluscum contagiosum, a highly contagious viral skin infection primarily affecting children ages 1 and above. The company launched Zelsuvmi commercially in July 2025 and has since built a 67-territory sales force targeting pediatric and adult dermatologists, general pediatricians, nurse practitioners, and physician assistants. Pelthos expanded its portfolio through acquisitions of two additional FDA-approved dermatological products: Xepi (ozenoxacin cream, 1%) for impetigo treatment, acquired from BioFrontera in October 2025 with planned relaunch in Q1 2027, and Xeglyze (abametapir lotion, 0.74%) for head lice, acquired from Hatchtech in December 2025 with planned launch in Q3 2027. All three products share overlapping healthcare provider call points, enabling commercial leverage. The company also holds contractual rights to pipeline assets based on the Nitricil platform, including SB207 for external genital and perianal warts (Phase 3), and potential future indications for atopic dermatitis and fungal infections. Pelthos trades on NYSE American under the ticker PTHS. Updated Aug 13, 2026